Allogene Therapeutics, Inc.

ALLONASDAQHealthcare● Active

$1.78

$-0.10(-5.31%)

Market Cap$434111910

P/E Ratio—

52W High$4.46

52W Low$0.98

Avg Volume9.8M

Open$1.91

Beta0.46

Overview

Allogene Therapeutics, Inc. (ALLO) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · ALLO · as of Jun 8, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.00

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 0%Active transactions only · RSU vesting excluded100% Sell ↓

Allogene Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 8, 2026

ALLO insider buying and selling by quarter

ALLO insider selling · ALLO insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

6.7M3.4M0

2024 Q2

2024 Q3

2024 Q4

2025 Q1

2025 Q2

2025 Q4

2026 Q1

2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 8, 2026

Active insiders

Most active in past 12 months · ALLO ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

ALLO executive sell shares · ALLO board member insider trading · ALLO insider trading SEC filing

Showing 54 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
Apr 21, 2026	Yoshiyama Annie SVP, Finance	Sale	9,586	$2.31	$22K	124,517	Form 4
Mar 31, 2026	Beneski Benjamin Machinas SVP, Chief Technical Officer	Sale	2,867	$2.50	$7K	195,338	Form 4
Mar 16, 2026	Beneski Benjamin Machinas SVP, Chief Technical Officer	Sale	4,835	$2.47	$12K	198,205	Form 4
Mar 16, 2026	Chang David D President and CEO · Director	Sale	47,763	$2.47	$118K	5,150,599	Form 4
Mar 2, 2026	Beneski Benjamin Machinas SVP, Chief Technical Officer	Sale	7,132	$2.60	$19K	203,040	Form 4
Feb 2, 2026	Beneski Benjamin Machinas SVP, Chief Technical Officer	Sale	7,549	$1.73	$13K	210,172	Form 4
Feb 2, 2026	Chang David D President and CEO · Director	Sale	95,269	$1.80	$171K	5,185,862	Form 4
Feb 2, 2026	Parker Geoffrey M. CHIEF FINANCIAL OFFICER	Sale	24,001	$1.76	$42K	1,252,795	Form 4
Feb 2, 2026	Douglas Earl Martin SVP, General Counsel	Sale	22,900	$1.76	$40K	564,948	Form 4
Feb 2, 2026	Yoshiyama Annie SVP, Finance	Sale	4,167	$1.72	$7K	130,322	Form 4
Feb 2, 2026	Roberts Zachary EVP of R&D	Sale	35,700	$1.77	$63K	581,166	Form 4
Jan 21, 2026	Roberts Zachary EVP of R&D	Sale	26,269	$1.56	$41K	616,866	Form 4
Dec 18, 2025	Kazam Joshua A Director	Option	47,700	—	—	350,763	Form 4
Nov 17, 2025	Beneski Benjamin Machinas SVP, Chief Technical Officer	Sale	786	$1.22	$959	217,721	Form 4
Oct 21, 2025	Parker Geoffrey M. CHIEF FINANCIAL OFFICER	Sale	36,744	$1.26	$46K	1,276,796	Form 4
Jun 10, 2025	MESSEMER DEBORAH M. Director	Sale	36,885	$1.42	$52K	107,431	Form 4
Apr 21, 2025	Yoshiyama Annie SVP, Finance	Sale	9,601	$1.41	$14K	130,663	Form 4
Mar 14, 2025	Chang David D President and CEO · Director	Sale	46,668	$1.96	$91K	5,276,569	Form 4
Mar 14, 2025	Beneski Benjamin Machinas SVP, Chief Technical Officer	Sale	5,488	$1.98	$11K	218,507	Form 4
Mar 1, 2025	Beneski Benjamin Machinas SVP, Chief Technical Officer	Award	31,755	—	—	223,995	Form 4
Feb 18, 2025	MESSEMER DEBORAH M. Director	Sale	13,313	$2.43	$32K	144,316	Form 4
Feb 3, 2025	Douglas Earl Martin SVP, General Counsel	Sale	6,404	$1.71	$11K	587,848	Form 4
Feb 3, 2025	Parker Geoffrey M. CHIEF FINANCIAL OFFICER	Sale	4,361	$1.73	$8K	1,301,540	Form 4
Feb 3, 2025	MOORE TIMOTHY L. Chief Technical Officer	Sale	14,746	$1.71	$25K	250,713	Form 4
Feb 3, 2025	Chang David D President and CEO · Director	Sale	46,003	$1.68	$77K	5,317,237	Form 4

Yoshiyama Annie

SVP, Finance

Sale

Date

Apr 21

9,586

Price

$2.31

Value

$22K

View Form 4 on SEC.gov

Beneski Benjamin Machinas

SVP, Chief Technical Officer

Sale

Date

Mar 31

2,867

Price

$2.50

Value

$7K

View Form 4 on SEC.gov

Beneski Benjamin Machinas

SVP, Chief Technical Officer

Sale

Date

Mar 16

4,835

Price

$2.47

Value

$12K

View Form 4 on SEC.gov

Chang David D

President and CEO · Director

Sale

Date

Mar 16

47,763

Price

$2.47

Value

$118K

View Form 4 on SEC.gov

Beneski Benjamin Machinas

SVP, Chief Technical Officer

Sale

Date

Mar 2

7,132

Price

$2.60

Value

$19K

View Form 4 on SEC.gov

Beneski Benjamin Machinas

SVP, Chief Technical Officer

Sale

Date

Feb 2

7,549

Price

$1.73

Value

$13K

View Form 4 on SEC.gov

Chang David D

President and CEO · Director

Sale

Date

Feb 2

95,269

Price

$1.80

Value

$171K

View Form 4 on SEC.gov

Parker Geoffrey M.

CHIEF FINANCIAL OFFICER

Sale

Date

Feb 2

24,001

Price

$1.76

Value

$42K

View Form 4 on SEC.gov

Douglas Earl Martin

SVP, General Counsel

Sale

Date

Feb 2

22,900

Price

$1.76

Value

$40K

View Form 4 on SEC.gov

Yoshiyama Annie

SVP, Finance

Sale

Date

Feb 2

4,167

Price

$1.72

Value

$7K

View Form 4 on SEC.gov

Roberts Zachary

EVP of R&D

Sale

Date

Feb 2

35,700

Price

$1.77

Value

$63K

View Form 4 on SEC.gov

Roberts Zachary

EVP of R&D

Sale

Date

Jan 21

26,269

Price

$1.56

Value

$41K

View Form 4 on SEC.gov

Kazam Joshua A

Director

Option

Date

Dec 18

47,700

Price

—

Value

—

View Form 4 on SEC.gov

Beneski Benjamin Machinas

SVP, Chief Technical Officer

Sale

Date

Nov 17

786

Price

$1.22

Value

$959

View Form 4 on SEC.gov

Parker Geoffrey M.

CHIEF FINANCIAL OFFICER

Sale

Date

Oct 21

36,744

Price

$1.26

Value

$46K

View Form 4 on SEC.gov

MESSEMER DEBORAH M.

Director

Sale

Date

Jun 10

36,885

Price

$1.42

Value

$52K

View Form 4 on SEC.gov

Yoshiyama Annie

SVP, Finance

Sale

Date

Apr 21

9,601

Price

$1.41

Value

$14K

View Form 4 on SEC.gov

Chang David D

President and CEO · Director

Sale

Date

Mar 14

46,668

Price

$1.96

Value

$91K

View Form 4 on SEC.gov

Beneski Benjamin Machinas

SVP, Chief Technical Officer

Sale

Date

Mar 14

5,488

Price

$1.98

Value

$11K

View Form 4 on SEC.gov

Beneski Benjamin Machinas

SVP, Chief Technical Officer

Award

Date

Mar 1

31,755

Price

—

Value

—

View Form 4 on SEC.gov

MESSEMER DEBORAH M.

Director

Sale

Date

Feb 18

13,313

Price

$2.43

Value

$32K

View Form 4 on SEC.gov

Douglas Earl Martin

SVP, General Counsel

Sale

Date

Feb 3

6,404

Price

$1.71

Value

$11K

View Form 4 on SEC.gov

Parker Geoffrey M.

CHIEF FINANCIAL OFFICER

Sale

Date

Feb 3

4,361

Price

$1.73

Value

$8K

View Form 4 on SEC.gov

MOORE TIMOTHY L.

Chief Technical Officer

Sale

Date

Feb 3

14,746

Price

$1.71

Value

$25K

View Form 4 on SEC.gov

Chang David D

President and CEO · Director

Sale

Date

Feb 3

46,003

Price

$1.68

Value

$77K

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 3

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About ALLO insider trading

ALLO insider trades

Allogene Therapeutics, Inc. (ALLO) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Beneski Benjamin Machinas (SVP, Chief Technical Officer), Yoshiyama Annie (SVP, Finance), Chang David D (President and CEO · Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. ALLO insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Allogene Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

ALLO insider trading · 5 questions

The insiders of Allogene Therapeutics, Inc. (ALLO) include executives and directors such as Beneski Benjamin Machinas (SVP, Chief Technical Officer), Yoshiyama Annie (SVP, Finance), Chang David D (President and CEO · Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

ALLO board member insider tradingwho are ALLO insidersALLO insider rosterAllogene Therapeutics, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026